All In Biotech

Drug Trial Radar · NCT03741127

Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101

Open Label, Multicenter, Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101

Last checked: Nov 20, 2026Latest source record: Mar 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Oct 29, 2018

Primary completion

Aug 2032

Study completion Nov 2032

Sponsor

Lead sponsor
Poseida Therapeutics, Inc.Industry
Sponsor type
Industry
Collaborators
California Institute for Regenerative Medicine (CIRM)
First posted
Nov 14, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Subjects are enrolled in this study following completion or early discontinuation from a Poseida sponsored or supported study of P-BCMA-101 T cells and will be followed for a total of 15 years post treatment from the last P-BCMA-101 treatment. Subjects will be monitored for safety and efficacy to assess the risk of delayed adverse events (AEs) and assess long-term efficacy, and PK and quantification of P-BCMA-101 T cells. Rimiducid may be administered as indicated.

Conditions

  • Multiple Myeloma

Interventions

  • Rimiducid may be administered as indicatedDrug

    Patients who received P-BCMA-101 in a previous trial will be evaluated in this trial for long term safety and efficacy. Rimiducid (safety switch activator) may be administered as indicated.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]Time frame: Treatment with P-BCMA-101 through year 15

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • University of California Davis

    Davis, California

  • University of California, San Diego

    San Diego, California

  • University of California San Francisco

    San Francisco, California

  • Colorado Blood Cancer Institute

    Denver, Colorado

  • University of Chicago

    Chicago, Illinois

  • University of Kansas Cancer Center

    Westwood, Kansas

  • University of Maryland Greenebaum Comprehensive Cancer Center

    Baltimore, Maryland

  • Johns Hopkins University

    Baltimore, Maryland

  • Wayne State - Karmanos Cancer Institute

    Detroit, Michigan

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • Sarah Cannon Research Institute at Tennessee Oncology

    Nashville, Tennessee

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • MD Anderson Cancer Center

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.